PURPOSE: To describe the clinical studies that led to the FDA approval of rituximab in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with chronic lymphocytic leukemia (CLL). MATERIALS AND METHODS: The results of two multinational, randomized trials in CLL patients comparing rituximab combined with fludarabine and cyclophosphamide versus FC were reviewed. The primary endpoint of both studies was progression-free survival (PFS). RESULTS: The addition of rituximab to FC decreased the risk of a PFS event by 44% in 817 previously untreated patients and by 24% in 552 previously treated patients. Median survival times could not be estimated. Exploratory analysis in patients older than 70 suggested that there was no benefit to patients when rituximab was added to FC. The safety profile observed in both trials was consistent with the known toxicity profile of rituximab, FC, or CLL. CONCLUSIONS: On the basis of the demonstration of clinically meaningful prolongation of PFS, the FDA granted regular approval to rituximab in combination with FC for the treatment of patients with CLL. The magnitude of the treatment effect in patients 70 years and older is uncertain.
PURPOSE: To describe the clinical studies that led to the FDA approval of rituximab in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with chronic lymphocytic leukemia (CLL). MATERIALS AND METHODS: The results of two multinational, randomized trials in CLL patients comparing rituximab combined with fludarabine and cyclophosphamide versus FC were reviewed. The primary endpoint of both studies was progression-free survival (PFS). RESULTS: The addition of rituximab to FC decreased the risk of a PFS event by 44% in 817 previously untreated patients and by 24% in 552 previously treated patients. Median survival times could not be estimated. Exploratory analysis in patients older than 70 suggested that there was no benefit to patients when rituximab was added to FC. The safety profile observed in both trials was consistent with the known toxicity profile of rituximab, FC, or CLL. CONCLUSIONS: On the basis of the demonstration of clinically meaningful prolongation of PFS, the FDA granted regular approval to rituximab in combination with FC for the treatment of patients with CLL. The magnitude of the treatment effect in patients 70 years and older is uncertain.
Authors: M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Tadeusz Robak; Anna Dmoszynska; Philippe Solal-Céligny; Krzysztof Warzocha; Javier Loscertales; John Catalano; Boris V Afanasiev; Loree Larratt; Christian H Geisler; Marco Montillo; Ilya Zyuzgin; Peter S Ganly; Caroline Dartigeas; András Rosta; Jörg Maurer; Myriam Mendila; M Wayne Saville; Nancy Valente; Michael K Wenger; Sergey I Moiseev Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544
Authors: Steven J Lemery; Jenny Zhang; Mark D Rothmann; Jun Yang; Justin Earp; Hong Zhao; Andrew McDougal; Anne Pilaro; Raymond Chiang; Joseph E Gootenberg; Patricia Keegan; Richard Pazdur Journal: Clin Cancer Res Date: 2010-07-02 Impact factor: 12.531
Authors: Barbara F Eichhorst; Raymonde Busch; Stephan Stilgenbauer; Martina Stauch; Manuela A Bergmann; Matthias Ritgen; Nicole Kranzhöfer; Robert Rohrberg; Ulrike Söling; Oswald Burkhard; Anne Westermann; Valentin Goede; Carmen D Schweighofer; Kirsten Fischer; Anna-Maria Fink; Clemens M Wendtner; Günter Brittinger; Hartmut Döhner; Bertold Emmerich; Michael Hallek Journal: Blood Date: 2009-07-15 Impact factor: 22.113
Authors: John C Byrd; Kanti Rai; Bercedis L Peterson; Frederick R Appelbaum; Vicki A Morrison; Jonathan E Kolitz; Lois Shepherd; John D Hines; Charles A Schiffer; Richard A Larson Journal: Blood Date: 2004-05-11 Impact factor: 22.113
Authors: Paolo Strati; Alessandra Ferrajoli; Susan Lerner; Susan O'Brien; William Wierda; Michael J Keating; Stefan Faderl Journal: Leuk Lymphoma Date: 2013-07-29
Authors: Danelle F James; Lillian Werner; Jennifer R Brown; William G Wierda; Jacqueline C Barrientos; Januario E Castro; Andrew Greaves; Amy J Johnson; Laura Z Rassenti; Kanti R Rai; Donna Neuberg; Thomas J Kipps Journal: J Clin Oncol Date: 2014-05-27 Impact factor: 44.544
Authors: Duan Wang; Linhao Li; Hui Yang; Stephen S Ferguson; Maria R Baer; Ronald B Gartenhaus; Hongbing Wang Journal: Blood Date: 2012-11-16 Impact factor: 22.113
Authors: Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps Journal: N Engl J Med Date: 2015-12-06 Impact factor: 91.245
Authors: Mark D Danese; Carolina M Reyes; Michelle L Gleeson; Marc Halperin; Sandra L Skettino; Joseph Mikhael Journal: Med Care Date: 2016-04 Impact factor: 2.983